Alnylam Pharmaceuticals
(ALNY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -174,101 | -1,131,156 | -923,663 | -517,743 | -240,341 |
| Depreciation Amortization | 26,079 | 44,468 | 60,665 | 40,015 | 19,778 |
| Income taxes - deferred | N/A | -1,433 | N/A | N/A | N/A |
| Accounts receivable | 19,153 | -45,597 | 7,672 | 46,095 | 39,696 |
| Accounts payable and accrued liabilities | -81,975 | 191,769 | 89,152 | 19,407 | -48,736 |
| Other Working Capital | -86,137 | 7,618 | -21,878 | -26,532 | -59,963 |
| Other Operating Activity | 130,506 | 393,057 | 378,756 | 144,746 | 118,373 |
| Operating Cash Flow | $-166,475 | $-541,274 | $-409,296 | $-294,012 | $-171,193 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -62,326 | 254,607 | 373,264 | 37,863 | -129,485 |
| PPE Investments | -13,891 | -72,059 | -50,424 | -33,914 | -17,859 |
| Purchase Of Investment | 0 | -8,500 | -8,500 | -8,500 | 0 |
| Other Investing Activity | 0 | -4,694 | -5,075 | -75 | -75 |
| Investing Cash Flow | $-76,217 | $169,354 | $309,265 | $-4,626 | $-147,419 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 135,393 | 898,277 | N/A | N/A |
| Debt Repayment | N/A | N/A | -762,107 | N/A | N/A |
| Common Stock Issued | 42,371 | 259,360 | 202,646 | 49,626 | 27,123 |
| Other Financing Activity | 4,000 | 31,000 | 23,500 | 15,667 | 7,833 |
| Financing Cash Flow | $46,371 | $425,753 | $362,316 | $65,293 | $34,956 |
| Exchange Rate Effect | 2,176 | -7,430 | -9,049 | -11,073 | -2,238 |
| Beginning Cash Position | 868,556 | 822,153 | 822,153 | 822,153 | 822,153 |
| End Cash Position | 674,411 | 868,556 | 1,075,389 | 577,735 | 536,259 |
| Net Cash Flow | $-194,145 | $46,403 | $253,236 | $-244,418 | $-285,894 |
| Free Cash Flow | |||||
| Operating Cash Flow | -166,475 | -541,274 | -409,296 | -294,012 | -171,193 |
| Capital Expenditure | -13,891 | -72,059 | -50,424 | -33,914 | -17,859 |
| Free Cash Flow | -180,366 | -613,333 | -459,720 | -327,926 | -189,052 |